Next Score View the next score

    Knome appoints Martin Tolar as chief executive

    Knome Inc., a Cambridge life sciences company specializing in human genome interpretation, today announced that it has appointed Martin Tolar, M.D., as its chief executive.

    Knome supports researchers with the informatics and software tools used to investigate the genetic basis of human disease and drug response.

    Before joining Knome, Tolar was chief executive of Normoxys Inc., where he helped build a management team, secure venture financings, and advance the company’s novel cancer therapeutics from a research project into clinical development, Knome said in a press release.


    Jorge Conde, Knome’s founding CEO, will become chief strategy officer and continue to serve on its board of directors, Knome said; in his new role, he will lead the development of Knome’s genome interpretation software and services.

    Chris Reidy can be reached at